Reuters
29 Sept 2026, 21:42 UTC · 2h ago
Verdict
Headline leans bullish. We score BAYN −0.60 across two claims.
Score contradicts the headline.
Leans bullish
From its wording — no explicit rating
−0.60strongly bearish
What the story claims
2 claims · scored −1 bearish … +1 bullish · 1 new · 1 priced in
Bayer is beginning a Missouri trial involving three cancer patients claiming Monsanto failed to adequately test Roundup.
Newtrial started 'on Tuesday'
So whatA loss here could reignite settlement pressure for the thousands of remaining claims, impacting cash reserves in FY2027.
More negative than 85% of claims this week
The outcome of this trial will test the viability of Roundup lawsuits following a US Supreme Court ruling in Bayer's favor earlier this year.
Continue reading
5 related stories
More negative than 76% of ticker scores this week
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
Priced inreferences earlier Supreme Court ruling
So whatPositive momentum from the SCOTUS win could lead to a valuation multiple expansion if this trial confirms a higher dismissal rate.
More positive than 67% of claims this week
Which stocks this story touches
More negative than 76% of ticker scores this week
The company faces a jury trial regarding allegations that its Monsanto unit failed to adequately test Roundup.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
4h ago
—
No price for BAYN right now — the quote feed didn't answer.
BAYN chart →
